Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MP1032 in Hospitalized Moderate to Severe COVID-19
NCT04932941Phase 2Completed
- Sponsor
- MetrioPharm AG
- Start
- Oct 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of mp1032 in coronavirus disease 2019 (COVID-19), sponsored by MetrioPharm AG. Started Oct 2021; status: completed.
02
Drugs
mp1032
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04932941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04932941.